| Eteplirsen in the treatment of Duchenne muscular dystrophy KR Lim, R Maruyama, T Yokota Drug Design, Development and Therapy 11, 533-545, 2017 | 1294* | 2017 |
| Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles QL Lu, A Rabinowitz, YC Chen, T Yokota, HF Yin, J Alter, A Jadoon, ... Proceedings of the National Academy of Sciences 102 (1), 198-203, 2005 | 490 | 2005 |
| Efficacy of systemic morpholino exon‐skipping in Duchenne dystrophy dogs T Yokota, Q Lu, T Partridge, M Kobayashi, A Nakamura, S Takeda, ... Annals of Neurology: Official Journal of the American Neurological …, 2009 | 485 | 2009 |
| Pathogenic exon-trapping by SVA retrotransposon and rescue in Fukuyama muscular dystrophy M Taniguchi-Ikeda, K Kobayashi, M Kanagawa, C Yu, K Mori, T Oda, ... Nature 478 (7367), 127-131, 2011 | 202 | 2011 |
| Bodywide skipping of exons 45–55 in dystrophic mdx52 mice by systemic antisense delivery Y Aoki, T Yokota, T Nagata, A Nakamura, J Tanihata, T Saito, ... Proceedings of the National Academy of Sciences 109 (34), 13763-13768, 2012 | 188 | 2012 |
| Restoring dystrophin expression in duchenne muscular dystrophy muscle: progress in exon skipping and stop codon read through EP Hoffman, A Bronson, AA Levin, S Takeda, T Yokota, AR Baudy, ... The American journal of pathology 179 (1), 12-22, 2011 | 174 | 2011 |
| Micro-dystrophin cDNA ameliorates dystrophic phenotypes when introduced into mdx mice as a transgene M Sakamoto, K Yuasa, M Yoshimura, T Yokota, T Ikemoto, M Suzuki, ... Biochemical and biophysical research communications 293 (4), 1265-1272, 2002 | 152 | 2002 |
| In-frame dystrophin following exon 51-skipping improves muscle pathology and function in the exon 52–deficient mdx mouse Y Aoki, A Nakamura, T Yokota, T Saito, H Okazawa, T Nagata, S Takeda Molecular Therapy 18 (11), 1995-2005, 2010 | 148 | 2010 |
| α1-Syntrophin modulates turnover of ABCA1 Y Munehira, T Ohnishi, S Kawamoto, A Furuya, K Shitara, M Imamura, ... Journal of Biological Chemistry 279 (15), 15091-15095, 2004 | 133 | 2004 |
| The status of exon skipping as a therapeutic approach to duchenne muscular dystrophy QL Lu, T Yokota, S Takeda, L Garcia, F Muntoni, T Partridge Molecular Therapy 19 (1), 9-15, 2011 | 125 | 2011 |
| Expansion of revertant fibers in dystrophic mdx muscles reflects activity of muscle precursor cells and serves as an index of muscle regeneration T Yokota, QL Lu, JE Morgan, KE Davies, R Fisher, S Takeda, TA Partridge Journal of cell science 119 (13), 2679-2687, 2006 | 110 | 2006 |
| Effects of systemic multiexon skipping with peptide-conjugated morpholinos in the heart of a dog model of Duchenne muscular dystrophy Y Echigoya, A Nakamura, T Nagata, N Urasawa, KRQ Lim, N Trieu, ... Proceedings of the National Academy of Sciences 114 (16), 4213-4218, 2017 | 106 | 2017 |
| Restoring Dystrophin Expression in Duchenne Muscular Dystrophy: Current Status of Therapeutic Approaches Y Shimizu-Motohashi, H Komaki, N Motohashi, S Takeda, T Yokota, ... Journal of Personalized Medicine 9 (1), 1, 2019 | 103 | 2019 |
| α1-Syntrophin–deficient skeletal muscle exhibits hypertrophy and aberrant formation of neuromuscular junctions during regeneration Y Hosaka, T Yokota, Y Miyagoe-Suzuki, K Yuasa, M Imamura, R Matsuda, ... The Journal of cell biology 158 (6), 1097-1107, 2002 | 94 | 2002 |
| Optimizing exon skipping therapies for DMD T Yokota, W Duddy, T Partridge Acta Myologica 26 (3), 179–184, 2007 | 93 | 2007 |
| Long-term efficacy of systemic multiexon skipping targeting dystrophin exons 45–55 with a cocktail of vivo-morpholinos in mdx52 mice Y Echigoya, Y Aoki, B Miskew, D Panesar, A Touznik, T Nagata, ... Molecular Therapy-Nucleic Acids 4, e225, 2015 | 85 | 2015 |
| Extensive and Prolonged Restoration of Dystrophin Expression with Vivo-Morpholino-Mediated Multiple Exon Skipping in Dystrophic Dogs T Yokota, A Nakamura, T Nagata, T Saito, M Kobayashi, Y Aoki, ... nucleic acid therapeutics 22 (5), 306-315, 2012 | 84 | 2012 |
| Optimization of antisense-mediated exon skipping for Duchenne muscular dystrophy K Dzierlega, T Yokota Gene Therapy, 2020 | 81 | 2020 |
| Viltolarsen for the treatment of Duchenne muscular dystrophy RR Roshmi, T Yokota Drugs Today 55 (10), 627-639, 2019 | 77 | 2019 |
| Multiple Exon Skipping in the Duchenne Muscular Dystrophy Hot Spots: Prospects and Challenges Y Echigoya, KRQ Lim, A Nakamura, T Yokota Journal of Personalized Medicine 8 (4), 41, 2018 | 77 | 2018 |
Rika MaruyamaUniversity of Alberta在 ualberta.ca 的电子邮件经过验证
